Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1892 - Pharmacokinetics and safety of FOLFOX therapy in patients undergoing hemodialysis


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancer in Special Situations


Taro Funakoshi


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


T. Funakoshi1, T. Horimatsu1, A. Yamada1, T. Kirishima2, T. Mizukami3, Y. Harada4, M. Nakajima5, S. Nakagawa6, T. Matsubara7, M. Yanagita7, M. Muto1

Author affiliations

  • 1 Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 606-8507 - Kyoto/JP
  • 2 Gastroenterology, Kyoto City Hospital, Kyoto/JP
  • 3 Clinical Oncology, St. Marianna University School of Medicine, Kawasaki/JP
  • 4 Hematology, Respiratory Medicine And Oncology, Faculty of Medicine, Saga University, Saga/JP
  • 5 Nephrology, Hitachi, Ltd., Hitachinaka General Hospital, Ibaraki/JP
  • 6 Clinical Pharmacology And Therapeutics, Kyoto University Hospital, Kyoto/JP
  • 7 Nephrology, Graduate School of Medicine, Kyoto University, Kyoto/JP


Abstract 1892


Due to a lack of information, there is no guideline regarding the dosage and timing of chemotherapy in cancer patients undergoing hemodialysis (HD). Therefore, we studied the pharmacokinetics of 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) in cancer patients undergoing HD.


HD patients (HD group) and patients with normal renal function (control group) who had received either modified FOLFOX6 therapy or modified FOLFOX7 therapy were prospectively enrolled. The blood concentrations of 5-FU and 5-FU metabolites, including α-fluoro-β-alanine (FBAL), fluoroacetic acid, and ammonia were measured using inductively coupled plasma-mass spectrometry. The blood concentrations of total and ultrafilterable platinum were measured in the HD group. To estimate the amount of L-OHP removal by dialysis, we also measured the platinum concentration in dialysate.


There were six patients in the HD group and eight patients in the control group. In the HD group, L-OHP was administered just before the HD session in four patients, and on a non-dialysis day in two patients. The amount of L-OHP removal by dialysis was 10% or less of the administered dose, and did not depend on the timing of L-OHP administration. Regarding the 5-FU metabolites, the blood concentration of FBAL was significantly higher in the HD group than in the control group (p 


The amount of L-OHP removal by dialysis was up to 10% regardless of the timing of L-OHP administration. Hyperammonemia should be monitored during FOLFOX therapy among HD patients.

Clinical trial identification

Legal entity responsible for the study

Onco-nephrology Consortium




M. Yanagita: Advisory board of Astellas and receives research grants from Astellas, Chugai, Daiichi Sankyo, Fujiyakuhin, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim, and Torii. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.